News

The growth problem of malignant tumors became actual for whole world. Annually cancer is taken away more than 8 millions of human lives. Such kind of tendency is demanded the adoption of more high technology methods of treatment in oncologic practice, diagnostics and medical- social rehabilitation of patients. Exactly, for this purpose, leading oncologists and radiologists of the world gathered on VII Congress of oncologists and radiologists of CIS countries at 5th-7th of September in Astana city. In this past event, it was blessed ground for held of expert dialogue in most high level, for constructive sharing of experience and making of concrete decisions that is concentrated on the struggle with oncological diseases.
  

LLP “VIVA PHARM” was participated in Congress together with our partners – “Merck Serono” company – with “Erbitux” (Cetuximab) injection for treatment of rectum and\or colon cancer, and for significant increasing of survivability among patients with recurrent and\or metastatic epidermoid cancer of head and neck. 

The satellite symposium was held in conclusion of first day of Congress; that is more than ordinary symposium: it was possible to feel that things, which are feeling the patients who have head and neck cancer – in new unique format. Professional actors performed to viewers the performance named “Senseless” with medical hidden motive; that staging was made by joint initiative of European community of head and neck researchers, Russian partnership of specialists who are working on tumors of head and neck, Association of specialists who are working on tumors of head and neck in Kazakhstan and “Merck Serono” company; it was directed to reduction of senseless losses of lives due to lack of knowledge about disease.  The staging is accompanied one patient with oncological disease through all steps of treatment (from first consultation till establishing of diagnosis and further, including treatment and other things after it), it is shown the whole drama of that way, it is helped to understand deeply how patient lives with head and neck cancer.

At this moment due to lack of suspicion about this disease among population, and  due to nonspecific character of symptoms, many patients with head and neck cancer are diagnosed in late stages, that is brought to worsening prognosis. Head and neck cancer are much effected on appearance, everyday life and it is hard to bear.  The results of additional researches were revealed the lack of training and information of patient, his big demand in empathy support from the side of medical workers; that is necessary for patient, that he could effectively manage with disease and its treatment in general. 

Organizers of performance and actors invited viewers to share with experience and vision of problem; and to help in the search of solutions to reduce senseless losses of people and expressed the hope, that after viewing they will be able to have additional stimulus to increase the level of education, awareness of specialists and support of patients with tumors of head and neck. We are also hope, that this initiative will entail the concrete actions and results, that is being brought benefit to all of us – to potential patients.

           

Many years “Merck Serono” company is devoted to development of new generation medicines for treatment of cancer, and its tasked – to provide patients by medicines, which selectively influenced on the cells of tumor.  “Erbitux” (Cetuximab) – is first injection in its class for target therapy from “Merck Serono Oncology” company, that injection was admitted by ASCO (American Society of Clinical Oncology) as main achievement in oncology in 2009-2011; and this is first injection during last 30 years, that is increased survivability during treatment of 1st line’s recurrent and\or metastatic head and neck cancer. In 1977, after appearance of chemotherapeutic agents that are contained platinum – this is first significant achievement in treatment of such patients (research of EXTREME). 

The modern researches were shown, that in development of many forms of cancer, especially feces-rectal and head and neck cancer, the key role is played receptors of epidermal growth factor – EGFR. “Erbitux” (Cetuximab) – is bound extracellular EGFR domains, blocked complex chain of reactions, that is brought to excrescence process of tissue, stimulated the self-destruction of mutate cells, prevented the development of multidrug resistance, stopped forming of new microvasculars in tissue (which is necessary for growth of tumor and development of metastasizes), activated its own system of antibodies, accelerated the cancer cells loss; “Erbitux” is depressed the growth of tumor and significantly increased effectiveness of standard therapy.

As Kazakhstan specialists and foreign guests of Congress had noted, the work of Kazakhstan in sphere of development of oncologic help is deserved respect in every possible way. In our dynamic-developed state, patients have free high-technological treatment that is appropriated to world standards and also expensive target and chemotherapeutic agents; it is being led the screening programs and cancer-registers.